


Ų.

Figure 2







Figure 4A






Figure 5A




Figure 5B




Figure 5C




Figure 5D




Figure 5E




Figure 5F





Figure 6A






Figure 7A




Figure 7B




Figure 8A




Figure 8B




Fig. 9




Figure 10A




Figure 10B




Figure 10C





Figure 10D









Figure 12

1st dimension: Isoelectric focusing



2nd dimension: SDS PAGE









Figure 17



,

Fig. 18








FIG. 19









Normalized marker peak area (marker/internal std):

Control

0.0

Disease

0.61

Drug treated

0.05

Retentate MapTM of Human Urine SELDI ProteinChipTM Array




FIG. 24





FIG. 25










FIG. 27






TGFβ (100 ng/ml 2.5xconditioned medium)

Fig. 27B








Figure 30




Figure 31




Figure 32





FIG. 33

Fig. 33A

Intensity

Fig. 33B



Mass/charge